Get the Stockscreener App
56.45
1.40%
0.78
After Hours:
56.64
0.19
+0.34%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $56.45, with a volume of 9.06M.
It is up +1.40% in the last 24 hours and down -3.70% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$55.67
Open:
$56.01
24h Volume:
9.06M
Relative Volume:
0.76
Market Cap:
$115.27B
Revenue:
$48.48B
Net Income/Loss:
$7.27B
P/E Ratio:
15.85
EPS:
3.5626
Net Cash Flow:
$11.91B
1W Performance:
-0.88%
1M Performance:
-3.70%
6M Performance:
+15.02%
1Y Performance:
+17.16%
1-Day Range:
$55.45
$57.02
1-Week Range:
$55.41
$57.40
52-Week Range:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
56.45 | 113.68B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
989.87 | 862.31B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
224.26 | 533.03B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
207.86 | 358.27B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
184.54 | 282.04B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
148.16 | 277.11B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal - BioWorld News
Bristol Myers Squibb (BMY) Valuation Check After Recent Share Weakness And Mixed 2024 Earnings - simplywall.st
Bristol Myers Squibb inks $15.2B drug deal with Hengrui - NJBIZ
BMS and Hengrui forge $15.2bn alliance for early-stage drugs - Pharmaceutical Technology
Bristol Myers, Hengrui Pharma Team Up in Global Drug Research Pact That Could Top $15B - MedCity News
Hengrui Pharma And Bristol Myers Squibb Forge $15.2 Billion Strategic Alliance Across Oncology And Immunology - BioPharma APAC
BMS and Hengrui Partner on 13 Oncology, Hematology, and Immunology Programs in Deal Worth Potentially $15.2 Billion - BioPharm International
BMO reiterates Bristol-Myers Squibb stock rating on Hengrui deal - Investing.com
Hengrui Pharma strikes $15.2 billion asset deal with BMS - The Pharma Letter
Hengrui Pharma and Bristol Myers Squibb Enter Strategic Collaboration to Advance Innovative Medicines - marketscreener.com
China's Hengrui, Bristol Myers Squibb sign collaboration, licensing deals - Reuters
AstraZeneca's Rare Disease Drug Shows Reduced Dependence On Calcium Supplements - Benzinga
Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion - BioPharma Dive
BMS-Hengrui Pact Highlights China’s Rising Role in Drug Development - PharmTech.com
Hengrui Pharma and Bristol Myers Squibb to advance innovative medicines across oncology, hematology, immunology - BioSpectrum Asia
BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal - BioSpace
China’s Hengrui Jumps After Inking USD15 Billion Innovative Drug Deal With BMS - Yicai Global
BMS, Hengrui strike $15.2B multi-asset pact - FirstWord Pharma
Hengrui & BMS Seal $15.2B Deal: China-US Pharma - Rediff MoneyWiz
Bristol Myers Squibb Expands Pipeline With Hengrui Multi Billion Drug Alliance - Yahoo Finance
Bristol Myers Squibb Strikes $15.2 Billion Drug Development Deal With Hengrui Pharma - Benzinga
Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B - Endpoints News
Hengrui, BMS Strike Huge $15.2bn Alliance For Bundle Of Preclinical Assets - Citeline News & Insights
Hengrui Pharma's Stock Jumps on Massive $1B Collaboration with Bristol-Myers - StockInvest.us
Bristol-Myers Inks Up to $15 Billion Licensing Deal With Hengrui - Bloomberg.com
Bristol Myers Squibb and China's Hengrui Pharma Forge Tie-Up - marketscreener.com
Bristol-Myers Squibb and China’s Hengrui Pharma Forge Tie-Up - WSJ
Hengrui Pharma shares surge on $1 bln Bristol-Myers partnership By Investing.com - Investing.com Nigeria
BMS inks $15B deal to bag Hengrui assets, tap China’s R&D speed - Fierce Biotech
Hengrui Pharma shares surge on $1 bln Bristol-Myers partnership - Investing.com
China’s Hengrui, Bristol Myers Squibb sign collaboration, licensing deals - WHTC
HENGRUI PHARMA (01276.HK) Surges Over 13% in PM After Striking Global Strategic Collaboration and Licensing Agreement with Bristol-Myers Squibb Company (BMY.US), to Receive USD950 million in Payments - AASTOCKS.com
Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology - The Manila Times
HENGRUI PHARMA (01276.HK) and Bristol-Myers Squibb Company (BMY.US) Enter Global Strategic Collaboration and License Agreement, Eligible for USD950 million in Related Payments - AASTOCKS.com
Jiangsu Hengrui Pharma Signs $15 Billion Drug Development Deal with Bristol Myers Squibb - marketscreener.com
Hengrui Pharma seals global collaboration and licensing deal with Bristol-Myers Squibb - TipRanks
Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors. - The Motley Fool
Bristol-Myers Squibb Company (BMY) Myers Beats Quarterly Profit Estimates - Insider Monkey
Bristol-Myers Squibb (BMY) Faces Stock Decline Despite Strong Q1 2026 Earnings - GuruFocus
Bristol Myers Squibb Company $BMY Position Boosted by Oxbow Advisors LLC - MarketBeat
Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting - Barchart.com
In FIFA-Tied Corporate Campaign, Bristol Myers Squibb 'Won't Lose' 05/05/2026 - MediaPost
Manning & Napier Advisors LLC Decreases Position in Bristol Myers Squibb Company $BMY - MarketBeat
LJI Wealth Management LLC Takes $2.11 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Crossmark Global Holdings Inc. Increases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Drucker Wealth 3.0 LLC Makes New $1.12 Million Investment in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb accused of buying off competitors to delay development of generic cancer drugs - Courthouse News
Employers Gain as Second Circuit Restricts Out-of-State Plaintiffs from Joining FLSA Collective Actions - Jackson Lewis
TiNivo-2 Completion: What Bristol-Myers Squibb’s Kidney Cancer Trial Means for Investors - TipRanks
BMY: Bristol Myers Squibb Secures EU Approval for Sotyktu in Pso - GuruFocus
EU approves Bristol Myers’ Sotyktu for psoriatic arthritis - Investing.com
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):